Sandu Pharmaceuticals Share Price Today | Stock Price & Sandu Pharmaceuticals Share Screener
As of October 5, 2026, the live Sandu Pharmaceuticals share price (BSE: SANDUPHQ) is ₹37.27, up 2.03% from the previous close, with shares trading between ₹35.33 and ₹38.00 in today's trading session, and a 52-week range of ₹30.52–₹46.12. Check SANDUPHQ 52-week performance for the annual price range and momentum. Use the Sandu Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Sandu Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Sandu Pharmaceuticals Share Price Chart
Track the current stock price of Sandu Pharmaceuticals with an interactive chart. Analyse SANDUPHQ share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Sandu Pharmaceuticals stock quote in one place.
The quote of ₹37.27 sits between the 52-week low of ₹30.52 and the 52-week high of ₹46.12, and the latest session moved 2.03% from the previous close.
Sandu Pharmaceuticals Company Profile - Fundamental Screener
Screen Sandu Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SANDUPHQ shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE751D01014.
Company Details
Classification
Identifiers and Leadership
Sandu Pharmaceuticals Balance Sheet Screener
Screen SANDUPHQ balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2025, total assets were ₹56, up from ₹52 in 2024.
Latest statistics put total assets at ₹56 and shareholder funds at ₹42.
| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
Assets |
|||
| Total Assets | 56 | 52 | 54 |
| Current Assets | 26 | 22 | 26 |
| Fixed Assets | 18 | 18 | 17 |
Liabilities |
|||
| Total Liabilities | 0 | 0 | 0 |
| Current Liabilities | 2 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 |
Shareholders' Equity |
|||
| Total Equity | 42 | 41 | 39 |
| Share Capital | 10 | 10 | 10 |
| Reserves & Surplus | 32 | 31 | 30 |
Sandu Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Sandu Pharmaceuticals income statement and profit fundamentals. Analyze SANDUPHQ quarterly results. Sandu Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2025-Mar, revenue was ₹14 and net profit was ₹0, equal to earnings per unit of ₹0.34, at an operating margin of 3%.
In that period expenses were ₹14, interest cost ₹0 and tax ₹0. The next period listed, 2024-Dec, shows revenue of ₹18 and net profit of ₹1.
| Item | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar | 2021-Sept | 2021-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 14 | 18 | 18 | 17 | 16 | 18 | 17 | 18 | 15 | 17 | 17 | 16 | 12 | 18 | 17 |
| Expenses | 14 | 17 | 17 | 17 | 15 | 17 | 16 | 17 | 15 | 16 | 16 | 16 | 11 | 17 | 17 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Operating Profit % | 3.00% | 5.00% | 5.00% | 2.00% | 4.00% | 3.00% | 5.00% | 2.00% | 3.00% | 5.00% | 5.00% | 2.00% | 5.00% | 5.00% | 4.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| EPS | 0.34 | 0.57 | 1.95 | 0.17 | 0.62 | 0.21 | 0.57 | 0.11 | 0.26 | 0.51 | 0.64 | 0.19 | 0.34 | 0.57 | 0.53 |
Sandu Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen SANDUPHQ cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹1.
Over the same period, investing activities provided ₹0 and financing activities used ₹1.
| Item | 2025-March | 2024-March | 2023-March |
|---|---|---|---|
Cash from Operations and Investing | |||
| Operating Activities | 1 | 1 | 0 |
| Investing Activities | 0 | -1 | 1 |
Financing and Net Cash | |||
| Financing Activities | -1 | -1 | 1 |
| Net Cash Flow | 0 | -1 | 1 |
Sandu Pharmaceuticals Shareholding Pattern Screener
See Sandu Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Sandu Pharmaceuticals promoter holding and ownership changes for SANDUPHQ on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 37.79%, foreign institutions 0.00%, domestic institutions 0.01% and the public 37.02%, spread across 10,268 shareholders.
The shareholder count was 10,268 in 2026-Jun, compared with 10,298 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 37.79% | 37.79% | 42.90% | 42.90% | 42.90% | 37.79% | 42.90% | 42.90% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 37.02% | 36.98% | 35.90% | 36.57% | 36.77% | 37.01% | 44.16% | 44.25% |
| Other Holding | 25.19% | 25.23% | 21.20% | 20.53% | 20.32% | 25.19% | 12.93% | 12.84% |
| Shareholder Count | 10,268 | 10,298 | 10,287 | 10,226 | 10,284 | 10,284 | 10,001 | 10,012 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Sandu Pharmaceuticals. Sandu Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.80 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.80 and ₹0.80 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.80 | 2.62% |
| 2024-March | ₹0.80 | 1.63% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.75 | 1.43% |
| 2021-March | ₹0.50 | 0.71% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Sandu Pharmaceuticals Stock Index Membership - Nifty & Sensex
See which indices include Sandu Pharmaceuticals stock. Check SANDUPHQ index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Sandu Pharmaceuticals Market Events Screener - Corporate Actions
Get Sandu Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Sandu Pharmaceuticals stock events that may affect SANDUPHQ share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 11, 2026, with a record date of September 11, 2026.
It is followed by Dividend dated September 4, 2026 and Quarterly Result Announcement dated August 11, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-11 | 2026-09-11 | Annual General Meeting | NA | -4.87% |
| 2026-09-04 | 2026-09-04 | Dividend | ₹ 1.00 /share | -9.00% |
| 2026-08-11 | 2026-08-11 | Quarterly Result Announcement | NA | 1.95% |
| 2026-05-05 | 2026-05-05 | Quarterly Result Announcement | NA | -1.85% |
| 2026-02-06 | 2026-02-06 | Quarterly Result Announcement | NA | 2.05% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -2.51% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -3.84% |
| 2025-09-18 | 2025-09-18 | Dividend | ₹ 0.80 /share | -12.97% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 0.76% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | 4.41% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -3.54% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | 2.33% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 3.42% |
| 2024-09-19 | 2024-09-20 | Dividend | ₹ 0.80 /share | 4.55% |
| 2023-09-18 | 2023-09-19 | Dividend | ₹ 0.75 /share | 41.02% |
Sandu Pharmaceuticals Competitors Screener - Peer Stocks Comparison
Screen SANDUPHQ competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Sandu Pharmaceuticals Company Announcements - News & Reports Screener
Screen SANDUPHQ latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated September 22, 2026 and September 12, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Intimation To The Holders Of Physical Securities To Furnish PAN And KYC Details | - |
| 2026-09-22 | Closure of Trading Window | - |
| 2026-09-12 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-09-12 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-09-12 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-11 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-20 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-19 | Announcement Under Regulation 30-Letter To Shareholder On Annual Report Weblink Whose Email Ids Are Not Registered With The Company/RTA | - |
| 2026-08-19 | Reg. 34 (1) Annual Report. | - |
| 2026-08-19 | Annual General Meeting To Be Held On 11Th September 2026 At 04:30 Pm Through Video Conferencing (VC)/ Other Audio Visual Means (QAVM) | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-11 | Approval Of Material Related Party Transactions Subject To Approval Of Shareholders | - |
| 2026-08-11 | Statement Of Deviation And Utilisation Of Funds For Q Ended 30.06.2026 | - |
| 2026-08-11 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-08-11 | Intimation About The Date Of The Annual General Meeting | - |
| 2026-08-11 | Intimation About The Record Date | - |
| 2026-08-11 | Intimation About Book Closure For AGM | - |
| 2026-08-11 | Outcome And Results Of The Board Meeting Dated 11.08.2026 Was Submitted On Time But Inadvertently No Digital Signature Was Affixed On The Covering Letter Further There Is No Change In The Contents Of The Outcome | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹37.27, within a 52-week range of ₹30.52 to ₹46.12. The P/E ratio is 22.48 and the P/B ratio is 1.05, with earnings per unit of ₹1.60. Market capitalisation stands at ₹35.31 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 3 balance sheet periods, 15 income statement periods, 3 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.